Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience

Background: Programmed death 1 (PD-1) inhibitors—tislelizumab, toripalimab, camrelizumab, and sintilimab—are used for advanced urothelial carcinoma (UC) in China. To date, the efficacy and adverse events (AEs) of these PD-1 inhibitors have been poorly reported for advanced UC. Methods: We reviewed 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Fengze, Wang, Dawei, Liu, Aina, Wang, Tianqi, Zhang, Dongxu, Yao, Huibao, Sun, Kai, Zhou, Zhongbao, Lu, Guoliang, Wu, Jitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971813/
https://www.ncbi.nlm.nih.gov/pubmed/35370654
http://dx.doi.org/10.3389/fphar.2022.837499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971813/
https://www.ncbi.nlm.nih.gov/pubmed/35370654
http://dx.doi.org/10.3389/fphar.2022.837499

Ejemplares similares